Q-omics provides the consensus-scored HNRNPA3P13 profile across patient tissues and cancer cell-line models. HNRNPA3P13 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, HNRNPA3P13 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, HNRNPA3P13 RNA expression shows 5,796 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, HNSC, and STAD as cancer lineages where HNRNPA3P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA3P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA3P13 survival associations across molecular data types. HNRNPA3P13 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA3P13 RNA expression–survival associations across cancer types. High HNRNPA3P13 expression shows unfavorable associations in LUSC, STAD, LUAD and CHOL, but favorable associations in KIRC and OV. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for HNRNPA3P13 RNA expression.
This table summarizes HNRNPA3P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPA3P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA3P13 shows higher tumor expression in HNSC, COAD, LUSC, BRCA, READ and PAAD. The HNSC box plot shows higher HNRNPA3P13 RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p = .002).
This table shows molecular features associated with HNRNPA3P13 in patient tissues and cancer cell lines. In patient samples, HNRNPA3P13 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
